Efficacy results from the EPCORE^TM NHL-1 study¹

The median follow-up time was 15.7 months (range: 0.3-23.5 months)³

Overall response rate (primary endpoint)¹

Complete response and median duration of response (secondary endpoints)¹

^*EPCORE^™ NHL-1 enrolled patients with ECOG status 0-2, de novo DLBCL, DLBCL transformed from indolent lymphoma, CAR-T naïve, prior CAR-T, and primary refractory disease.
^†Patients who had relapsed or were refractory to prior CAR-T cell therapy were eligible if ≥30 days since last CAR-T cell treatment.
^‡ORR was determined by Lugano criteria (2014) as assessed by Independent Review Committee (IRC).
^§A patient is considered to be primary refractory if they are refractory to frontline anti-lymphoma therapy.
^||A patient is considered to be refractory if they experience disease progression or stable disease as best response or disease progression within 6 months after therapy completion.
^aClassified using MedDRA version 24.1. CRS events and ICANS events were graded per Lee et al; clinical tumor lysis syndrome was graded per Cairo-Bishop criteria. All other events were graded per National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0.^4,5
b24 patients had CRS that was a maximum of grade 2 in severity; of these, 19 patients had hypotension, including 6 with concurrent hypoxia and 13 without concurrent hypoxia, and did not receive vasopressor treatment.
^cPyrexia not considered CRS by the investigator.
^dOne fatal case of ICANS was reported.